XML 28 R27.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

INTANGIBLE ASSETS, NET (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: | The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:
|  | December 31, 2019 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Amount |  |  | Weighted- Average Remaining Amortization Period (yrs.) |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Approved hormone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
therapy drug |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
candidate patents |  | $ | 3,463,082 |  |  | $ | (478,983 | ) |  | $ | 2,984,099 |  |  |  | 13 |
Hormone therapy drug |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
candidate patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
(pending) |  |  | 1,979,299 |  |  |  | — |  |  |  | 1,979,299 |  |  |  | n/a |
Non-amortizable intangible |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multiple trademarks |  |  | 294,813 |  |  |  | — |  |  |  | 294,813 |  |  |  | indefinite |
TOTAL |  | $ | 5,737,194 |  |  | $ | (478,983 | ) |  | $ | 5,258,211 |  |  |  |  |
|  | December 31, 2018 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Amount |  |  | Weighted- Average Remaining Amortization Period (yrs.) |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OPERA software patent |  | $ | 31,951 |  |  | $ | (10,484 | ) |  | $ | 21,467 |  |  |  | 10.75 |
Development costs of |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
corporate website |  |  | 91,743 |  |  |  | (91,743 | ) |  |  | — |  |  |  | n/a |
Approved hormone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
therapy drug |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
candidate patents |  |  | 2,234,129 |  |  |  | (282,485 | ) |  |  | 1,951,644 |  |  |  | 14 |
Hormone therapy drug |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
candidate patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
(pending) |  |  | 1,855,279 |  |  |  | — |  |  |  | 1,855,279 |  |  |  | n/a |
Non-amortizable intangible |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multiple trademarks |  |  | 264,289 |  |  |  | — |  |  |  | 264,289 |  |  |  | indefinite |
TOTAL |  | $ | 4,477,391 |  |  | $ | (384,712 | ) |  | $ | 4,092,679 |  |  |  |  |
Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: | Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:
Year Ending December 31, |  | Estimated Amortization
2020 |  | $229,546
2021 |  | $229,546
2022 |  | $229,546
2023 |  | $229,546
2024 |  | $229,546

X
- Definition Tabular disclosure of intangible assets, which may be broken down by major class. + References No definition available. + Details
Name: | txmd_ScheduleOfIntangibleAssetsTableTextBlock
Namespace Prefix: | txmd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration